radio immunothérapie pré ciblée (Frampas et al. 2013), p.113 ,
-sucDf-Fe s'attache à un résidu lysine de l'anticorps. 1. La transformation ? - Références bibliographiques ANSM, 2011. ,
URL : https://hal.archives-ouvertes.fr/halshs-00408978
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome, Blood, vol.109, issue.8, pp.3489-95, 2007. ,
DOI : 10.1182/blood-2006-08-040410
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation, Blood, vol.99, issue.6, pp.2185-91, 2002. ,
DOI : 10.1182/blood.V99.6.2185
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, vol.114, issue.10, pp.2068-76, 2009. ,
DOI : 10.1182/blood-2009-03-213280
Beta-2-Microglobulin in Myeloma: Optimal Use for Staging, Prognosis, and Treatment--a Prospective Study of 160 Patients, Blood, vol.63, issue.2, pp.468-76, 1984. ,
The Phenotype of Normal, Reactive and Malignant Plasma Cells. Identification of 'Many and Multiple Myelomas' and of New Targets for Myeloma Therapy, Haematologica, vol.91, issue.9, pp.1234-1274, 2006. ,
Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?, Cancer, vol.9, issue.6, pp.1334-1379, 2002. ,
DOI : 10.1002/cncr.10818
Lorvotuzumab mertansine: antibody-drug-conjugate for CD56??? multiple myeloma, Frontiers in Bioscience, vol.19, issue.1, pp.163-70, 2014. ,
DOI : 10.2741/4202
Distribution of Absorbed Dose around Point Sources of Electrons and Beta Particles in Water and Other Media, Journal of Nuclear Medicine, vol.5, pp.5-23, 1971. ,
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma, Proceedings of the National Academy of Sciences, vol.93, issue.24, pp.13931-13967, 1996. ,
DOI : 10.1073/pnas.93.24.13931
Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside, Leukemia, vol.19, issue.10, pp.1729-1767, 2005. ,
DOI : 10.1034/j.1600-065X.2003.00035.x
Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?, European Journal of Nuclear Medicine, vol.19, issue.3, pp.205-218, 1992. ,
DOI : 10.1007/BF00173283
Synthesis and in Vitro Characterization of a Dendrimer???MORF Conjugate for Amplification Pretargeting, Bioconjugate Chemistry, vol.19, issue.8, pp.1518-1543, 2008. ,
DOI : 10.1021/bc8001024
213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma, Journal of Nuclear Medicine, vol.54, issue.9, pp.1597-1604, 2013. ,
DOI : 10.2967/jnumed.112.111997
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC, Cancer Immunology, Immunotherapy, vol.30, issue.12, pp.1841-1890, 2013. ,
DOI : 10.1007/s00262-013-1493-8
Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma, Cancer Research, vol.72, issue.6, pp.1395-1406, 2012. ,
DOI : 10.1158/0008-5472.CAN-11-0188
Validation of 213Bi-Alpha Radioimmunotherapy for Multiple Myeloma, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.5, pp.3165-3170, 1999. ,
Immunoscintigraphy for cancer detection: ???A thousand ills require a thousand cures???, Journal of Cancer Research and Clinical Oncology, vol.47, issue.Suppl, pp.1-15, 1992. ,
DOI : 10.1007/BF01192305
Uptake of the Cation hexakis(2-Methoxyisobutylisonitrile)- Technetium-99m by Human Carcinoma Cell Lines in Vitro, Cancer Research, vol.50, issue.7, pp.2198-2202, 1990. ,
Imaging in Multiple Myeloma Recent Results in Cancer Research, Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer, vol.183, pp.133-180, 2011. ,
PET imaging with 89Zr: From radiochemistry to the clinic, Nuclear Medicine and Biology, vol.40, issue.1, pp.3-14, 2013. ,
DOI : 10.1016/j.nucmedbio.2012.08.004
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma, Leukemia, vol.22, issue.9, pp.1545-56, 2009. ,
DOI : 10.1136/bmj.307.6897.172
A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, vol.126, issue.3, pp.842-54, 1975. ,
DOI : 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system, European Journal of Cancer, vol.42, issue.11, pp.42-1539, 1990. ,
DOI : 10.1016/j.ejca.2005.11.037
Whole-Body (18)F-FDG PET Identifies High-Risk Myeloma, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol.43, issue.11, pp.1457-63, 2002. ,
18F-Fluoride Positron Emission Tomography and Positron Emission Tomography/Computed Tomography, Seminars in Nuclear Medicine, vol.37, issue.6, pp.462-69, 2007. ,
DOI : 10.1053/j.semnuclmed.2007.07.002
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy, Blood, vol.97, issue.6, pp.1566-71, 2001. ,
DOI : 10.1182/blood.V97.6.1566
Staging Monoclonal Plasma Cell Disease: Comparison of the Durie-Salmon and the Durie-Salmon PLUS Staging Systems, Radiology, vol.257, issue.1, pp.195-204, 2010. ,
DOI : 10.1148/radiol.10091809
Evaluation de La Réponse Thérapeutique En Cancérologie: Place de L'imagerie Isotopique, 2006. ,
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report, Cancer Research, vol.64, issue.4, pp.1546-58, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-2876
18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma, Journal of Nuclear Medicine, vol.49, issue.2, pp.195-200, 2008. ,
DOI : 10.2967/jnumed.107.045641
Improvement of Radioimmunotherapy Using Pretargeting, Frontiers in Oncology, vol.3, p.159, 2013. ,
DOI : 10.3389/fonc.2013.00159
Radionuclides for Radioimmunotherapy: Criteria for Selection, The International Journal of Biological Markers, vol.8, issue.3, pp.180-86, 1993. ,
A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies, Cancer Research, vol.74, issue.4, pp.1179-89, 2014. ,
DOI : 10.1158/0008-5472.CAN-13-1589
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process, Blood, vol.91, issue.1, pp.3-21, 1998. ,
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.360, issue.25, pp.961-70, 2009. ,
DOI : 10.1056/NEJMct0805626
Evaluation of the Skeletal Kinetics of Fluorine-18-Fluoride Ion with PET, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol.33, issue.5, pp.633-675, 1992. ,
Tc-Labeled Bivalent MORF, Molecular Pharmaceutics, vol.7, issue.4, pp.1118-1142, 2010. ,
DOI : 10.1021/mp9002909
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914689
Immunogenicity of engineered antibodies, Methods, vol.36, issue.1, pp.3-10, 2005. ,
DOI : 10.1016/j.ymeth.2005.01.001
Imaging of Low-Grade Bone Infection with a Technetium-99m Labelled Monoclonal Anti-NCA-90, 2002. ,
Fragment in Patients with Previous Joint Surgery, European Journal of Nuclear Medicine and Molecular Imaging, vol.29, issue.4, pp.547-51 ,
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development, Clinical Cancer Research, vol.11, issue.22, pp.7967-85, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-1302
Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-97, 1975. ,
DOI : 10.1038/256495a0
Zevalin™: 90Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin ??? s Lymphoma, Current Pharmaceutical Biotechnology, vol.2, issue.4, pp.341-390, 2001. ,
DOI : 10.2174/1389201013378545
Fluorescence In Situ Hybridization Analysis Shows the Frequent Occurrence of 14q32.3 Rearrangements with Involvement of Immunoglobulin Switch Regions in Myeloma Cell Lines, Cancer Genetics and Cytogenetics, vol.109, issue.2, pp.99-107, 1999. ,
DOI : 10.1016/S0165-4608(98)00157-5
Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49, Cancer Biology & Therapy, vol.9, issue.8, pp.767-74, 2010. ,
DOI : 10.1007/s00259-005-1853-5
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093915
Adding a Clearing Agent to Pretargeting Does Not Lower the Tumor Accumulation of the Effector as Predicted, Cancer Biotherapy & Radiopharmaceuticals, vol.25, issue.6, pp.757-62, 2010. ,
DOI : 10.1089/cbr.2010.0800
Y labeled Phosphorodiamidate Morpholino Oligomer for Pretargeting Radiotherapy, Bioconjugate Chemistry, vol.22, issue.12, pp.2539-2584, 2011. ,
DOI : 10.1021/bc200366t
Tumor Pretargeting in Mice Using (99m)Tc-Labeled Morpholino, a DNA Analog, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol.43, issue.3, pp.384-91, 2002. ,
Technetium-99m sestamibi scanning in multiple myeloma stem cell transplantation, Leukemia & Lymphoma, vol.84, issue.5-6, pp.5-6, 1996. ,
DOI : 10.1016/S0025-6196(12)61101-X
Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma, British Journal of Haematology, vol.47, issue.4, pp.723-752, 1999. ,
DOI : 10.1046/j.1365-2141.1997.1122939.x
A facile method for the labeling of proteins with zirconium isotopes, Nuclear Medicine and Biology, vol.23, issue.4, pp.439-487, 1996. ,
DOI : 10.1016/0969-8051(96)00020-0
Phase III Trial of Consolidation Therapy With Yttrium-90???Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-64, 2008. ,
DOI : 10.1200/JCO.2008.17.2015
Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma, Diagnostic and Interventional Imaging, vol.94, issue.6, pp.629-665, 2013. ,
DOI : 10.1016/j.diii.2013.01.005
Toward theragnostics, Critical Care Medicine, vol.37, issue.Supplement, pp.50-58, 2009. ,
DOI : 10.1097/CCM.0b013e3181921349
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging, European Journal of Nuclear Medicine and Molecular Imaging, vol.37, issue.2, pp.250-59, 2010. ,
DOI : 10.1007/s00259-009-1263-1
Characterization of Multidrug Resistance P-Glycoprotein Transport Function with an Organotechnetium Cation, Biochemistry, vol.34, issue.38, pp.12210-12230, 1995. ,
DOI : 10.1021/bi00038a015
Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review, British Journal of Haematology, vol.118, issue.1, pp.50-61, 2013. ,
DOI : 10.1111/bjh.12346
Thrombus Imaging with Indium-111 and Iodine-131-Labeled Fibrin- Specific Monoclonal Antibody and Its F(ab')2 and Fab Fragments, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol.29, issue.7, pp.1212-1234, 1988. ,
Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients, Tumor Biology, vol.32, issue.5, pp.679-88, 2012. ,
DOI : 10.1007/s13277-012-0362-y
Fluoride Kinetics of the Axial Skeleton Measured in Vivo with Fluorine-18-Fluoride PET, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol.38, issue.12, pp.1970-76, 1997. ,
Human Anti- Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy, Cancer Research, vol.45, issue.2, pp.879-85, 1985. ,
Preparation, characterization and biological evaluation of cationic 99Tc/99mTc-dioxime complexes, Nuclear Medicine and Biology, vol.20, issue.3, pp.317-341, 1993. ,
DOI : 10.1016/0969-8051(93)90054-X
Molecular imaging agents: impact on diagnosis and therapeutics in oncology, Expert Reviews in Molecular Medicine, vol.48, p.20, 2010. ,
DOI : 10.1088/0031-9155/53/12/R01
89Zr Radiochemistry for Positron Emission Tomography, Medicinal Chemistry, vol.7, issue.5, pp.389-94, 2011. ,
DOI : 10.2174/157340611796799186
Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment, Mediators of Inflammation, vol.7, issue.12, pp.1-7, 2011. ,
DOI : 10.1182/blood-2003-02-0380
Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma, Blood, vol.99, issue.4, pp.1305-1318, 2002. ,
DOI : 10.1182/blood.V99.4.1305
Signal characteristics of focal bone marrow lesions in patients with multiple myeloma using whole body T1w-TSE, T2w-STIR and diffusion-weighted imaging with background suppression, European Radiology, vol.177, issue.4, pp.857-62, 2011. ,
DOI : 10.1007/s00330-010-1950-0
Current and future imaging modalities for multiple myeloma and its precursor states, Leukemia & Lymphoma, vol.43, issue.9, pp.1630-1670, 2011. ,
DOI : 10.1158/1078-0432.CCR-08-2310
PET (positron emission tomography) imaging of biomolecules using metal???DOTA complexes: a new collaborative challenge by chemists, biologists, and physicians for future diagnostics and exploration of in vivo dynamics, Organic & Biomolecular Chemistry, vol.243, issue.5, pp.815-843, 2008. ,
DOI : 10.1039/b718157b
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients, Expert Opinion on Pharmacotherapy, vol.120, issue.12, pp.1569-73, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-3352
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies, Blood Cancer Journal, vol.16, issue.10, p.41, 2011. ,
DOI : 10.1038/bcj.2011.42
18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: A systematic review, Cancer, vol.37, issue.iii, pp.1971-81, 2012. ,
DOI : 10.1002/cncr.26467
89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol.44, issue.8, pp.1271-81, 2003. ,
Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias, Journal of Nuclear Medicine, vol.53, issue.7, pp.1091-1101, 2012. ,
DOI : 10.2967/jnumed.111.098830
Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma, Leukemia, vol.19, issue.2, pp.275-78, 2005. ,
DOI : 10.1038/sj.leu.2403586
Rapid Tumor Penetration of a Single-Chain Fv and Comparison with Other Immunoglobulin Forms, Cancer Research, vol.52, issue.12, pp.3402-3410, 1992. ,
Radioimmunotherapy for lymphoma, Current Opinion in Oncology, vol.11, issue.5, pp.375-80, 1999. ,
DOI : 10.1097/00001622-199909000-00009
PET Tracers Based on Zirconium-89, Current Radiopharmaceuticalse, vol.4, issue.2, pp.131-170, 2011. ,
DOI : 10.2174/1874471011104020131